Guggenheim initiated coverage of Metsera (MTSR) with a Buy rating and $56 price target The firm sees a “highly promising multi-billion ...

Goldman Sachs analyst Chris Shibutani initiated coverage of Metsera (MTSR) as an Early-Stage Biotech. Metsera is clinical-stage ...

New research finds older women achieve the best results with weight loss injections – thanks to consistent tracking and ...

Weight loss medications like Wegovy and Zepbound are gaining popularity as millions turn to them for quick results and ...

Hims & Hers said on Monday that it may no longer be able to sell compounded versions of the weight-loss drug made by Novo ...

While the outcomes can be positive, Consumer Reports warns there are important considerations, especially for older adults, ...

Weight loss drugs like Ozempic bring health gains, but at what costs to relationships? Couples must face new challenges as ...